Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anxin Formula (also known as Huoxue Anxin Recipe or HAR) is a traditional Chinese herbal medicine formula used primarily for the treatment of coronary heart disease (CHD). It contains a combination of multiple herbal ingredients and has been shown in preclinical studies to exert anti-oxidative effects, promote myocardial angiogenesis, improve cardiac function after myocardial infarction, down-regulate blood coagulation, regulate collagen biosynthesis, inhibit peroxidation and inflammation injury, and promote cholesterol efflux. The mechanism involves modulation of several biological targets including complement C3 (C3), fibrinogen alpha (FGA), fibrinogen gamma (FGG), interleukin-6 (IL6), and apolipoprotein A1 (APOA1). These actions contribute to its cardioprotective effects. The formula is not a single pharmaceutical agent but rather a multi-component herbal preparation[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anxin Formula.